Atrial Fibrillation in the Young: A Neurologist’s Nightmare by Aggarwal, Nikhil et al.
Review Article
Atrial Fibrillation in the Young: A Neurologist’s Nightmare
Nikhil Aggarwal,1,2 Subothini Selvendran,1,2 Claire E. Raphael,1,2 and Vassilios Vassiliou1,2
1Department of Cardiology, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
2Imperial College, London, UK
Correspondence should be addressed to Vassilios Vassiliou; vassiliou@doctors.org.uk
Received 28 August 2014; Revised 19 March 2015; Accepted 20 March 2015
Academic Editor: Mamede de Carvalho
Copyright © 2015 Nikhil Aggarwal et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia seen in clinical practice with prevalence in excess of
33 million worldwide. Although often asymptomatic and until recently considered a “benign” arrhythmia, it is now appreciated
that thromboembolism resulting from AF results in significant morbidity and mortality predominantly due to stroke. Although an
arrhythmia more commonly affecting the elderly, AF can also occur in the young. This review focuses on the impact of AF in the
younger population and discusses the dilemmas of managing younger patients with AF.
1. Introduction
What do American former professional basketball player
Larry Bird, former British Prime Minister Tony Blair, and
Mother Theresa have in common? Surprisingly they have all
suffered from atrial fibrillation (AF) [1–3]. AF is the most
common sustained cardiac arrhythmia in clinical practice
and affects 1-2% of the general population and in excess of
33 million worldwide [4]. Although AF becomes increasingly
more prevalent with aging, it also affects young people; 0.5%
of people under 40 years of age suffer from AF, with >5% of
those over 65 and >10% of those more than 80 years of age
being affected [5]. Despite AF being a documented cause of
stroke for a long time [6], until recently it was still considered
a relatively “benign” arrhythmia [7]. AF is a significant
contributor to cardiovascular morbidity and mortality and is
frequently more symptomatic and troublesome in the young,
often causing significant impairment to quality of life [5, 8, 9].
But what does it mean when a person suffers from AF?
2. What Is AF?
In normal sinus rhythm there is a coordinated contraction of
both atria and ventricles, but AF occurs when the atria of the
heart receive random electrical impulses causing rapid and
ineffective atrial contraction followed by irregularly irregular
ventricular contractions [8, 10].
There are three types of AF: paroxysmal, persistent, and
permanent. Paroxysmal AF can usually last from a few sec-
onds up to a few days but the key feature is that this subsides
spontaneously [11]. Persistent AF can last for any period of
time; it is possible to restore sinus rhythm; however, an inter-
vention is required either in the form of pharmacotherapy
or electrical cardioversion or ablation for this to be achieved.
Finally, permanent AF is present all the time and it is either
not possible to restore sinus rhythm or deemed inappropriate
to attempt cardioversion [11].
AF in the young can often be precipitated by hyperten-
sion, hyperthyroidism, or valvular heart disease as well as
by certain lifestyle factors such as alcohol consumption and
even smoking [12]. Avoiding these factors can prevent future
AF attacks [5]. For the purposes of this review article the
term young is used to capture adults under the age of 50. AF
can cause many hemodynamic changes that can potentially
lead to thromboembolic events, with stroke being the most
dreaded complication. While stroke is more common in
elderly patients with AF, it can also affect the younger pop-
ulation. In fact, one study by Sanak et al. shows the incidence
of AF in a population of patients aged less than 50 with
acute stroke to be as high as 11% with 70% of these having
paroxysmal AF [13]. Strokes relating to AF can be more
debilitating than non-AF related strokes [14], and this can be
particularly life-changing, especially in the young.Therefore,
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not only doesAF lead tomortality but it can lead to significant
morbidity with increased distress suffered by the patient and
the family and associated with an increased cost for the
community [4]. It is also important to highlight that younger
patients withAFhave highermortality thanmatched controls
without a diagnosis of AF. Andersson and colleagues found
patients who were admitted into hospital with incidental AF
had worse prognosis when compared to patients without
AF and that the risk of all-cause mortality was greater in
the younger age group compared to the over-75-year-old
population [15].
Despite its common prevalence, the management of AF
can be difficult and controversial for the population as a
whole. In recent years, however, by understanding the under-
lying pathophysiological mechanisms of this arrhythmia
and the associated risks, various therapeutic options are
currently utilized [8]. Nonetheless trying to balance the Scylla
of thromboembolic stroke against the Charybdis of major
bleeding complications in the young can be evenmore tricky,
especially as young patients often have a lower thromboem-
bolic risk and hence the absolute benefit of anticoagulation
is less, whilst at the same time they are asked to commit
to many years of anticoagulation with increasing overall
absolute degree of bleeding risk.
3. Mechanism
For many years there were only speculative theories for the
precise mechanism of AF. Over the last thirty years, however,
many animal models and patient clinical studies have begun
to clarify the underlying pathophysiology of this complex
arrhythmia [16].
In normal sinus rhythm, islets of atrial myocardium and
vascular smooth muscle in the coronary sinus and atri-
oventricular valves maintain synchronized electrical activity.
In AF, ectopic foci occurring in “pockets” of atrial tissue
within the pulmonary veins or atria can develop delayed
depolarization leading to the arrhythmia’s initiation. Many
factors including sympathetic or parasympathetic stimula-
tion, bradycardia, atrial premature beats, or tachycardia and
acute atrial stretch [17] are thought to cause AF, although
these factors are usually required in association with other
contributors.
One study by Ha¨ıssaguerre and colleagues demonstrated
impulses from a single focus in the pulmonary veins prop-
agating to the atria as fibrillatory waves [18]. Furthermore,
additional work from the same group supported this theory
as they showed that radiofrequency ablation of the foci
terminated AF [19]. However, newer evidence supports that
structural aswell as electrophysiological abnormalities lead to
the development of AF. Frustaci and colleagues showed that
atrial hypertrophy and fibrosis were more frequently present
in patients with AF, supporting the theory that fibrosis
itself could drive AF [20]. Furthermore, and more pertinent
to young patients with AF, there is some recent evidence
to suggest that, in patients with lone AF, the arrhythmia
can be actually associated with structural atrial disease
recently defined as “fibrotic atrial cardiomyopathy” [21].
In this situation, scarring within the atria may disrupt the
normal pathways of conduction, leading to the initiation
of atrial fibrillation. Imaging using cardiovascular magnetic
resonance may allow detection of focal areas of fibrosis,
both in the atria and in the ventricle. Similarly, areas of
inflammation within the atria may also act as a focus for
arrhythmia, producing “irritable” myocardium that is more
arrhythmogenic. Unlike ventricular inflammation, imaging
of atrial inflammation is challenging and this process may
therefore be underappreciated. Another study by Stiles and
colleagues confirmed atrial conduction abnormalities such
as longer effective refractory period, longer conduction time
along linear catheters, and slower conduction velocity as the
cause of AF initiation and progression [22].
Athletes have also been shown to have higher prevalence
of AF. It is thought that prolonged and strenuous exercise
can predispose to AF [23] by relating to structural heart
changes and in particular bigger left atria and left ventricles
when compared to controls [24]. However, there could be
an additional adrenergic and vagal component in this [25].
Furthermore, other structural heart conditions including
hypertrophic cardiomyopathy (HCM) have been shown to
have an increased incidence of AF. Darby and DiMarco,
for example, have shown that the incidence of AF in HCM
patients is in the region of 22% [26]. Older patients often
present with hemodynamic instability due to the increasing
prevalence of heart failure with age [27]; however, young
patients with HCM and AF are at increased risk of symp-
tomatic congestive heart failure, stroke, and even sudden
cardiac death [26].
It is also well established that atrial electrophysiological
properties are influenced by any changes in autonomic tone.
Patients with structural heart disease often have AF, which
is triggered by the sympathetic nervous system, for example,
during episodes of sepsis or drug provocation, for example,
with dobutamine. However those without structural heart
disease can have AF mediated through the parasympathetic
nervous system, through the vagus nerve. The exact mech-
anism by which foci are triggered is not known but it is
thought that the close interaction between nerves and atrial
myocytes can play a part [28]. In young patients particularly,
it was found that there was a shift towards vagal dominance
in lone AF and nocturnal paroxysmal AF [29]. Furthermore,
it is known that in patients with paroxysmal AF and syncope
there is an abnormal neural response even in sinus rhythm
and AF can actually trigger vasovagal syncope [30].
Furthermore, inflammatory markers such as C-reactive
protein and interleukin-6 have been implicated in AF initi-
ation and progression. While an association has been iden-
tified, further work is required to confirm this and elucidate
the underlying mechanisms [5, 31]. These findings together
support the notion that AF is not merely a problem with
the “electrics” of the heart but that structural and anatomical
abnormalities predispose toAFdevelopment. Initiation ofAF
in an individual anatomically predisposed to AF may result
from tachy- or bradyarrhythmias, infection, and inflamma-
tion.
Finally, perhaps a less emphasized cause of atrial fibril-
lation is due to specific genetic defects. The last decade in
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Figure 1: Cardiovascular magnetic resonance (CMR) image of a patient with AF in the early phase following gadolinium administration.
On the left image demonstrates thrombus (white arrow) in the LAA and on the right 6 months later, following anticoagulation therapy with
warfarin and confirming resolution of the thrombus.
particular has seen an expansion in our understanding of
the inherited form of the arrhythmia [32]. The familial form
of AF is uncommon and research into its pathophysiology
is still being carried out; however, it is more prevalent in
younger patients [32, 33]. It is believed that a small percentage
of cases are associated with changes in the KCNE2, KCNJ2,
andKCNQ1 genes, which are inherited through an autosomal
dominant pattern [34]. These genes are responsible for ion
transportation and play a critical role in maintaining the
heart’s normal sinus rhythm [34] and in the future they
can perhaps aid in identifying young individuals at risk of
developing AF at an earlier stage.
4. Diagnosing AF
Thediagnosis of AF is suspected when the pulse is irregularly
irregular and indeed in the United Kingdom all family prac-
titioners are advised to check the pulse for any irregularity
in everyone over the age of 65 [35]. An absent 𝛼 wave in
the jugular venous pulse is diagnostic of AF but sensitivity
is poor. The diagnosis is confirmed by electrocardiography
(EKG). The absence of P waves and an irregularly irregular
ventricular response are diagnostic of AF on a 12-lead EKG.
If the EKG demonstrates atrial flutter (whenmultiple P waves
exist with each QRS complex), rather than AF, this should
be treated in the same way as AF, as atrial flutter too can
lead to thromboembolism. Although this review focuses on
young patients with AF, the management of patients with
atrial flutter is exactly the same [14]. In cases of suspicion
of paroxysmal atrial fibrillation (or flutter) depending on the
frequency of the palpitations, a 24-hourmonitor or prolonged
(5–7day) recorder or even an implantable loop recorder (ILR)
can be used to identify AF [14]. Clinically, patients often
present with breathlessness, palpitations, chest pain, and
dizziness. Young patients are much more likely to present
with palpitations than the elderly. However, the elderly are
much more likely to present with anginal chest pain in con-
trast to young patientswho are known to presentwith atypical
chest pain [5]. Once AF has been confirmed the clinical
examination should look for signs that may suggest predis-
posing factors such as hypertension, exophthalmos or goiter
for thyrotoxicosis, heart murmurs for valvular heart disease,
displaced apex beat for cardiomyopathy, prominent second
heart sound (P2) supporting pulmonary arterial hyper-
tension, respiratory wheeze, crackles or cyanosis supporting
chronic obstructive pulmonary disease, and evidence for
prior thromboembolic disease as a result of the AF.
5. How Does AF Lead to Stroke?
The ineffective atrial contraction often leads to blood pooling
in the atria.This pooling can then lead to thrombus formation
due to blood stasis and subsequent fragmentation and dis-
persion in the arterial circulation can cause thromboembolic
strokes and transient ischemic attacks (TIA) [4]. The most
likely location for a thrombus is the left atrium and particu-
larly the left atrial appendage (LAA). In fact for up to 90% of
patients with nonvalvular AF in whom a thrombus has been
identified, it is in the LAA as shown in Figure 1 [36].The LAA
is prone to blood stasis due to its long and tubular structure
[4] and, furthermore, fibrillation can lead to decreased left
atrial appendage flow velocities and decreased contractility
[37], further increasing the risk of thrombosis in accordance
to Virchow’s triad [38].
Due to their large size, cardiac emboli flow to the intra-
cranial vessels and in most cases can cause massive, super-
ficial, single large striatocapsular or multiple infarcts in the
middle cerebral artery territory.This stops the flow of oxygen
to the brain and this brain anoxia leads to brain cell death
[39]. In the posterior circulation, cardioembolism can pro-
duce Wallenberg’s syndrome, cerebellar infarcts, top-of-the-
basilar syndrome, multilevel infarcts, or posterior-cerebral-
artery infarct [39].
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It is however important to note that AF is not the only
cause of cerebral infarction in the young. Although rare,
a paradoxical embolism through a defect in the interatrial
septum (such as a patent foramen ovale (PFO) or atrial septal
defect (ASD)) can allow small emboli to pass from the venous
to the arterial and then cerebral circulation causing a stroke
[40, 41]. A PFO is commonly found in the healthy population
with up to 25–30% of people having a PFO [42]. Therefore
in any patient with stroke and presence of PFO this should
not be automatically considered as causative and a search
for other explanations for the stroke, including paroxysmal
AF, should be initiated. Other rare causes for stroke in the
young include vasculitis, Takayasu’s arteritis, and Behc¸et’s
syndrome which can both cause thrombi [43], infections
such as bacterial endocarditis [44], and myeloproliferative
disorders particularly polycythemia rubra vera [45]. Patients
may also have procoagulative states such as antithrombin III
deficiency, protein C and S deficiencies, or hereditary con-
ditions such as hyperhomocystinemia and factor V Leiden
[46].The use of oral contraceptive pills, or recreational drugs
[47], cerebral hemorrhage secondary to congenital aneu-
rysms, arteriovenous malformations, or hypertension are
other recognized causes of stroke in the young [48].
6. How Does Stroke Affect Patients?
Following a stroke, patients can experience loss of vision,
dizziness, trouble communicating, loss of balance, and dif-
ficulty swallowing [49]. Furthermore, they often describe a
“lack of control” over their bodies, not knowing when or
where the weakness will stop [50], as well as shock and fear
when their bodies became weaker. This can lead to sleepless
nights, full of anxiety, which is further aggravated by the fact
that they may not be able to turn and move themselves [51].
Healthcare workers commonly come across stroke patients
who have depression and this is even more frequent in
the young [52]. Questions like “why bother to teach me
how to dress? I won’t be able to do it anyway” are often
asked indicating a vulnerable population that could benefit
from significant support [53]. Furthermore, perhaps more
so in the young, patients often worry how their relationship
with their partner, including sexual activity [54], and friends
might change and whether people might start viewing them
differently; as for those still in full-time education they are
worried about how the stroke will affect their performance
and consequently their future careers.
7. Preventing a Stroke in a Patient with AF
In every patient with AF, stroke is the most dreaded com-
plication, and as such doctors and patients should work
together to try and minimize the risk for this. It is not pos-
sible to eliminate the risk completely, but it is now possible
to estimate relatively accurately the thromboembolic risk
for each patient and therefore try and personalize medical
therapy. Using a validated risk assessment score such as the
CHA
2
DS
2
-VASc demonstrated in Table 1, which has been
recently developed to help healthcare practitioners assess
Table 1: Demonstrating the recently described CHA2DS2-VASc
thromboembolic risk score for patients with AF. It has a maximum
of nine points where more points equate to higher thromboembolic
risk as shown in Table 2.
CHA2DS2-VASc Condition
Points
allocated
C
Congestive heart failure or
left ventricular (LV)
dysfunction with ejection
fraction (EF) ≤40%
1
H Hypertension 1
A2 Age ≥ 75 2
D Diabetes 1
S2
Transient ischemic attack
(TIA), stroke, or other
thromboembolisms
2
V
Vascular disease (e.g.,
peripheral artery disease,
myocardial infarction, and
aortic plaque)
1
A Age 65–74 1
Sc Sex category, that is, female 1
Table 2: Using the CHA2DS2-VASc score, an annual adjusted risk
score for stroke can be estimated and the benefits of anticoagulation
considered.
CHA2DS2-VASc score Risk (annual adjusted risk)
0 0%
1 1.3%
2 2.2%
3 3.2%
4 4.0%
5 6.7%
6 9.8%
7 9.6%
8 6.7%
9 15.2%
thromboembolic risk, clinicians can estimate this risk and
have more accurate discussions with the patients [55]. They
can assess the need of oral anticoagulants (OAC) and also
othermedical therapies to ensure other risk factors that could
increase stroke risk (such as hypertension, hypercholes-
terolemia, and diabetes) are adequately controlled [14]. The
HAS-BLED (hypertension, abnormal renal/liver function,
stroke, bleeding history or predisposition, labile international
normalized ratio, the elderly (> 65 years), and drugs/alcohol
concomitantly) scoring system helps assess the individual’s
bleeding risk in AF patients to further support clinical
decision-making regarding anticoagulants [56]. A score of
greater than 3 shows the patient is very prone to bleeding
and therefore must be monitored frequently [57]. After
full assessment, family doctors, cardiologists, and increas-
ingly neurologists are called to make a decision based on
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the thromboembolic risk of the individual and their bleeding
tendency as to whether the benefits of anticoagulation are
likely to outweigh the risks associated with it. It may well be
that in a young patient with no evidence of any structural
heart disease or hypertension anticoagulation is not started
due to a lower risk score using traditional scoring systems
for thromboembolic risk (e.g., CHA
2
DS
2
-VASc = 0 or 1)
[58]. It is however important to consider anticoagulation
in all patients, as OACs have been shown to have a major
preventative role in cardioembolism in AF [59]. Since there is
less evidence base in the young, we favor discussion between
cardiology and neurology for individual cases. Although the
risk score may give a lower annual risk of further stroke,
it is important to appreciate that, in the younger person
with a greater life expectancy, they are exposed to this
risk for a longer period of time and it may therefore be
appropriate to have a lower threshold for anticoagulation
providing that the hemorrhagic risk is acceptable. Vitamin
K antagonists are very effective in reducing stroke risk. In
fact, studies have shown that dose-adjusted warfarin with a
target INR of between 2 and 3 leads to a 64% decrease in
the relative risk reduction of ischemic stroke [60]. Although
warfarin is very effective, it has many interactions with
other drugs and also many dietary interactions. Coupling
this with the need for frequent blood monitoring, patients
often find it very unappealing especially in the young who
face anticoagulation for many years [61]. More recently,
other novel oral anticoagulant (NOAC) drugs have been
approved by Food and Drugs Administration (FDA) and
European Medicines Agency (EMA) including dabigatran
etexilate, a direct thrombin inhibitor, and apixaban and
rivaroxaban, two direct factor Xa inhibitors [62].These drugs
have been shown to be at least as affective as warfarin with
a possible lower risk of bleeding in older populations but
have not been formally assessed in the younger patients who
were perhaps underrepresented in these studies [63, 64].
Although extremely appealing, mainly because of the lack of
requirement of blood monitoring, these drugs are fairly new
and so all the possible side effectsmay not as yet be known [7].
This can be especially important in a young person with AF
facing the prospect of anticoagulation for many decades and
the possibility of rare idiosyncratic potentially serious side
effects. Despite this, their current uptake has been increasing
mainly due to their convenience and is supported by the
current guidance [14, 65] but the long-term safety of NOACs
in young people is still awaited. Antiplatelet medication such
as aspirin and clopidogrel, which were once frequently used
in the thromboembolic risk reduction of patients with AF,
should only be used infrequently nowadays. The stroke risk
reduction with a single antiplatelet agent is only modest
at best (10% in a meta-analysis) [66] and as such these
drugs can only be recommended for patients with minimal
thromboembolic risk [14]. Naturally all reversible causes of
AF and ischemic stroke in the young should be excluded
before anticoagulation is started or continued indefinitely.
Furthermore, young patients in particular should have reg-
ular risk assessments as the indication for anticoagulation
may change. It is becoming more clear that with increasing
OACoptions available forAF this is becomingmore complex.
The decision to choose which anticoagulant for which patient
assuming that the patient would benefit from anticoagulation
is particularly difficult in the young. It is therefore important
to discuss the more complex cases at a multidisciplinary
setting including neurologists and cardiologists.
Historically, a rhythm control strategy (i.e., aiming to
restore sinus rhythm) was considered superior to simply
controlling the rate of ventricular escape rhythm in AF [67].
However, the AFFIRM trial showed that rate control was at
least as good as rhythm control in symptomatic AF [68].
Controlling symptoms in young patients particularly with
paroxysmal AF and rapid ventricular rates is difficult with
just rate control however [67]. If patients continue to expe-
rience symptoms after at least one antiarrhythmic drug then
consideration of AF ablation is recommended. Typically the
ideal candidates for AF ablation are younger patients without
structural heart disease and before persistent AF develops
[67]. Catheter ablation has been found to be associated with
shorter hospitalization, fewer complications, and favorable
clinical outcomes in young patients with paroxysmal AF
[69]. The cornerstone of radiofrequency ablation for AF is
electrical pulmonary vein isolation, which isolates triggers
of AF activity in the pulmonary vein and therefore stops
AF. More recently increasingly complex ablation techniques
have been used in an attempt to increase the success of the
procedure including atrial substrate modification, targeting
complex fractionated electrograms, ligament of Marshall
ablation, ablation of ganglion plexi, linear ablation, focal
impulse or rotor modulation, and rapid drivers/dominant
frequency [70].
8. Investigations in Acute Stroke
In an acute stroke brain imagingwith a computer tomography
(CT) ormagnetic resonance imaging (MRI) should be carried
out immediately [71]. This can help exclude a hemorrhagic
stroke and may identify an area of ischemia supporting the
use of thrombolysis [72]. Other investigations, which can be
helpful in identifying the cause of a stroke in a young person
include: transthoracic echocardiography (TTE), prolonged
EKG recording and CT or MRI angiography of the great
vessels [73]. Transesophageal echocardiography (TEE) is
indicated in patients where TTE is not diagnostic. A TTE can
show dilated left atrium, right to left shunting, and possibly
a PFO/ASD [74] but cannot however show a thrombus in
the LAA, the leading cause of stroke due to AF which can be
clearly seen with a TEE, cardiac MRI, or CT [14].
If all the above tests prove inconclusive and the stroke
remains cryptogenic (cerebral ischemia/infarction due to
unknown origin [73]), management becomes more complex
as lack of knowledge of the cause of the stroke makes treat-
ment more challenging.
9. Prevention of AF
Although a positive family history has been shown in up
to a quarter of patients with AF, there are still many risk
factors, which can be optimized to reduce the burden of AF
[75–77]. Risk factors particularly pertinent to young patients
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include exercise, obesity, smoking, hypertension, and alcohol
[5]. Long-term consumption of alcohol and binge drinking,
which is particularly common in young people, has also
been shown to increase the risk of AF by 37% and has been
associated with as much as 60% of new onset AF in patients
under the age of 65 [78, 79].This is in contrast to older people
where the major risk factors of AF include hypertension,
coronary heart disease, heart failure, valvular heart disease,
thyroid disorders, and diabetes [80]. Some of these risk
factors can be reduced by maintaining a healthy lifestyle
with regular mild-moderate physical activity and a balanced
diet low in saturated fats and cholesterol. Blood pressure
should be managed and a healthy weight maintained. Other
underlying conditions including sleep apnea, thyroid disease,
and diabetes, which can contribute to AF, should also be
controlled [5]. The thromboembolic risk in AF in the young
is more difficult to manage as the benefits of long-term
anticoagulation should be balanced against the bleeding risk,
as illustrated through the following cases.
Case 1. A 23-year-old male right-handed bricklayer with no
significant past medical history presents to the emergency
room (ER) on a Saturday night. He had been out drinking for
the evening and he noticed some palpitations about 3 hours
previously. On examination there was no hemodynamic
instability and cardiac auscultation was normal. The pulse
was irregularly irregular and the initial EKG showed AF with
a heart rate of 130 bpm.A repeat EKG30minutes later showed
spontaneous reversion to normal sinus rhythm. He was
observed overnight where he remained in sinus rhythm and
was discharged the followingmorning. He was referred to the
joint cardiology/neurology AF assessment clinic in the hos-
pital as well as being given lifestyle advice on binge drinking.
It is not an uncommon scenario to see patients presenting
following significant binge drinking with AF. In this example,
on taking a full history, the patient had in excess of 20 units
of alcohol the evening prior to his admission in casualty.
This reverted back to sinus rhythm without needing any
pharmacotherapy. A 24-hour EKG monitoring prior to the
clinic assessment showed normal sinus rhythm with no
episodes of arrhythmias and his transthoracic echocardio-
gram was completely normal. In particular there was no
valvular abnormality, his ventricular systolic function was
normal, and his left atrial size was normal indicating that
he was unlikely to have had significant continuous episodes
of atrial fibrillation. His blood parameters including renal,
liver, and thyroid functions were normal.There was no family
history of cardiac disease or AF.
What needs to be addressed in the outpatient clinic is why
he got AF and how he should be managed in the longer term,
in terms of both arrhythmia prevention and management of
his thromboembolic risk. In the absence of any structural
heart abnormalities and biochemical abnormalities and with
no family history it would be acceptable to consider the
heavy alcohol intake on the day of the presentation to ER
as the trigger of AF. Anticoagulation would not be recom-
mended as the cause for his AF is reversible. He should
refrain from drinking heavily and this is likely to prevent
further AF attacks. This should be explained to him when
seen in the outpatient appointment. At the same time his
thromboembolic risk profile needs to be considered and if
he has any evidence of hypertension or hypercholesterolemia,
this should be treated accordingly. He should also be advised
to present in ER in the future, ideally within 12 hours from the
onset of any similar episodes (to facilitate chemical/electrical
cardioversion if necessary), and importantly refrain from
driving himself to ER in case of very rapidAF that could cause
hemodynamic compromise. His family practitioner should
be informed of this episode and involved in his future care,
particularly in ensuring that there are no further episodes
of fibrillation and that this person refrains from drinking
excessively in the future.
Case 2. A 24-year-old female right-handed semiprofessional
tennis player presented with an acute attack of right facial
and armweakness. She consulted her family physician within
an hour of the event. The family physician undertook an
EKG and identified new onset AF. Her past medical history
included well treated hypertension andmigraines.The family
physician was worried that this could represent an acute
stroke and referred her to the neurology department for
further investigations and management.
Her risk factors for AF include hypertension and also sig-
nificant exercise training [81]. The concern here in the acute
phase is whether her weakness might represent migraine
or a thromboembolic event. In this case an urgent brain
MRI confirmed an acute ischemic stroke in the left middle
cerebral artery distribution. However, although she had some
weakness, this rapidly improved after initial presentation and
did not meet criteria for acute stroke thrombolysis. She was
admitted for observation and also had a TTE. The TTE
demonstrated slightly dilated right ventricular dimensions
with a dilated left atrium and normal left ventricular systolic
function, in keeping with an “athlete’s heart.” There was
no evidence of an intra-atrial shunt at rest or on bubble
study. Given the AF and recent stroke, anticoagulation with
warfarin as first line would be appropriate. To reduce the
risk of hemorrhagic transformation of the cerebral infarction,
anticoagulation is usually started 14 days after the event [14]
and only once blood pressure is controlled. To reduce throm-
boembolic risk, anticoagulation should continue lifelong
as her thromboembolic risk is high (CHA
2
DS
2
-VASc = 4,
conferring a risk of adjusted stroke risk of 4% per year
without anticoagulation as shown in Table 1). In terms of
restoring sinus rhythm it may be appropriate to refer her
for electrophysiological studies and percutaneous pulmonary
vein isolation/AF ablation. Although this could restore sinus
rhythm and prevent potential cardiomyopathy relating to the
AF, she will need to remain on anticoagulation lifelong as the
risk of thromboembolism will remain even if an AF ablation
is apparently successful [14]. She should also continue to
have outpatients review (ideally once annually) to assess her
thromboembolic risk and ensure that any additional factors
(e.g., hypertension) are well controlled.
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Case 3. A 20-year-old male left-handed engineering student
presents with signs of an acute right middle cerebral artery
stroke. An urgent computer tomography (CT) of the brain
excluded brain hemorrhage and he was promptly thrombol-
ysed in ER. The following morning when assessed he was
found to have made a good recovery. His EKG demonstrated
AF and a TTE showed normal left ventricular systolic func-
tion with normal size left atrium and additionally demon-
strated a patent foramen ovale (PFO). His management was
discussed in a joint neurology/cardiology meeting.
This is a complex case of a young man presenting with
a stroke and two possible etiologies: the AF and PFO. It
would be important to identify which one is responsible for
the stroke as it might facilitate different treatment. If we
hypothesize that the PFO was responsible for the stroke then
this would have meant that the venous thrombus (usually
from the lower limbs) moved from the right (venous) side of
the heart through the atrial septum to the left (arterial) side
of the heart and embolized in the brain. It would be useful to
undertake bilateral lower limb ultrasonography to rule out a
deep vein thrombosis. If he had any symptoms to suggest a
pulmonary embolus then a CT pulmonary angiogram could
be undertaken to look for this. If a source for a peripheral
thrombus can be identified then it would be logical to assume
that the stroke was secondary to embolization through the
PFO and support percutaneous closure of this to prevent
further similar events [82]. A TEE could also be undertaken;
this will allow further visualization of the left atrium and
left atrial appendage looking for any evidence of thrombus
there, which would suggest that the AF is the likely culprit
for the stroke.This could also be used to further visualize the
size and anatomy of the PFO. In the absence of peripheral
thrombus and given that PFOs are very common, affecting
up to 25–30% of the population [83], it would be reasonable
to consider that the PFO is not related to this stroke, in the
presence of AF, a more likely contributor. The AF should
therefore be managed with anticoagulation 14 days after the
event (as in the case above) and further management for
restoration of sinus rhythm could be considered. Chemical or
electrical cardioversion or electrical catheter ablation could
be considered at a later stage. Like Case 2, this patient should
be anticoagulated for life in view of his thromboembolic risk
(CHA
2
DS
2
VASc = 2, conferring a risk of adjusted stroke
risk of 2.2% per year without anticoagulation) and reviewed,
ideally annually initially in the outpatient clinic, to ensure that
other factors that could contribute to his thromboembolic
risk are addressed.
10. Conclusion
AF is the most common cardiac arrhythmia contributing
to significant morbidity and mortality. Although a disease
predominantly of the elderly, AF also affects young people.
Thromboembolic disease and particularly stroke in the young
can lead to increased long-term morbidity, which can affect
relationships, education, and employment. Anticoagulation
can reduce the risk of thromboembolism in the young with
AF; however such a decisionmust not be taken lightly in view
of the long-term risk of bleeding seen with all anticoagulants.
Close liaison anddiscussion between patients, family doctors,
cardiologists, and neurologists can allow the best manage-
ment of patients with AF and particularly in young ones.
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